GNPX

SEC source: 0001437749-26-012463 · rdgdoc.xml · nonDerivative · entry 2

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Longnecker Associates Ltd

Disclosed balance after: 0

F1 · shares: Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes.

SEC source: 0001437749-26-012463 · rdgdoc.xml · nonDerivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,157

F1 · shares: Represents shares sold by the Reporting Person on April 14, 2026 for tax purposes.

SEC source: 0001437749-26-006153 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Director · President, CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,331

F1 · shares: Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).

SEC source: 0001437749-26-006154 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,692

F1 · shares: Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).

SEC source: 0001437749-25-038736 · rdgdoc.xml · nonDerivative · entry 1

Moreno Toscano Jose Antonio · CIK 0001807313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,157

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests 100% upon the earlier of (a) August 15, 2026 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.

SEC source: 0001437749-25-038732 · rdgdoc.xml · nonDerivative · entry 1

Wilson William R Jr. · CIK 0001807385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,157

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests 100% upon the earlier of (a) August 15, 2026 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.

SEC source: 0001437749-25-038734 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Director · President, CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,661

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.

SEC source: 0001437749-25-038733 · rdgdoc.xml · nonDerivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,165

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests 100% upon the earlier of (a) August 15, 2026 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025 (the "RSS").

SEC source: 0001437749-25-038735 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,860

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025, the "EIP") and vests in installments of 50% on February 27, 2026 and the remaining 50% on February 27, 2027, provided that the recipient continues to serve as a Service Provider (as defined in the Company's EIP) through the applicable vesting dates. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-50 reverse stock split of the Company's Common Stock effected as of October 21, 2025.

SEC source: 0001437749-25-021817 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Director · President, CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,968

F1 · shares: Represents shares withheld on June 30, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

SEC source: 0001437749-25-021819 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,971

F1 · shares: Represents shares withheld on June 30, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

SEC source: 0001437749-25-004464 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Director · President, CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,743

F1 · shares: Represents shares withheld on February 18, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

SEC source: 0001437749-25-004466 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,471

F1 · shares: Represents shares withheld on February 18, 2025 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

SEC source: 0001437749-24-036886 · rdgdoc.xml · nonDerivative · entry 1

Moreno Toscano Jose Antonio · CIK 0001807313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,845

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% upon the earlier of (a) June 30, 2025 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the amount of securities beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's common stock effected as of February 2, 2024.

SEC source: 0001437749-24-036884 · rdgdoc.xml · nonDerivative · entry 1

Wilson William R Jr. · CIK 0001807385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,845

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% upon the earlier of (a) June 30, 2025 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the amount of securities beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's common stock effected as of February 2, 2024.

SEC source: 0001437749-24-036880 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Director · President, CEO and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,138

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% as of June 30, 2025, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-24-036882 · rdgdoc.xml · nonDerivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,220

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% upon the earlier of (a) June 30, 2025 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

F2 · balance_after: This total represents the amount of securities beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's common stock effected as of February 2, 2024 (the "RSS").

SEC source: 0001437749-24-036878 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,056

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests 100% as of June 30, 2025, provided that the recipient continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-24-005055 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,763

F1 · shares: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024.

SEC source: 0001437749-24-005062 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,806

F1 · shares: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

F2 · balance_after: This total represents the number of shares of Common Stock beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024.

SEC source: 0001437749-24-005058 · rdgdoc.xml · nonDerivative · entry 1

Varner John Rodney · CIK 0001735543 · Director · Chairman, President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,352

F1 · shares: Represents shares withheld on February 18, 2024 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan.

F2 · balance_after: This total represents the number of shares of Common Stock directly beneficially owned following this reported transaction and the 1-for-40 reverse stock split of the Company's Common Stock effected as of February 2, 2024 (the "RSS").

SEC source: 0001437749-23-018943 · rdgdoc.xml · nonDerivative · entry 1

Moreno Toscano Jose Antonio · CIK 0001807313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,795

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted pursuant to the Genprex, Inc. (the "Company") Amended and Restated Outside Director Compensation Policy. One hundred percent (100%) of the RSUs shall vest upon the earlier of (a) the one (1) year anniversary of June 27, 2023 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the Outside Director continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-018939 · rdgdoc.xml · nonDerivative · entry 1

Wilson William R Jr. · CIK 0001807385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,795

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted pursuant to the Genprex, Inc. (the "Company") Amended and Restated Outside Director Compensation Policy. One hundred percent (100%) of the RSUs shall vest upon the earlier of (a) the one (1) year anniversary of June 27, 2023 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the Outside Director continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-018941 · rdgdoc.xml · nonDerivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,795

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted pursuant to the Genprex, Inc. (the "Company") Amended and Restated Outside Director Compensation Policy. One hundred percent (100%) of the RSUs shall vest upon the earlier of (a) the one (1) year anniversary of June 27, 2023 and (b) the day prior to the Company's next annual meeting of stockholders occurring after the grant date, provided that the Outside Director continues to serve as a Service Provider (as defined in the Company's 2018 Equity Incentive Plan) through the applicable vesting date. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-010869 · rdgdoc.xml · nonDerivative · entry 1

VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,000

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001437749-23-010871 · rdgdoc.xml · nonDerivative · entry 1

Varner John Rodney · CIK 0001735543 · Director · Chairman, President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · by Alizzita Ltd

Disclosed balance after: 20,800

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0299 to $1.07 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001437749-23-004243 · rdgdoc.xml · nonDerivative · entry 1

VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,000

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-004237 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,499

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-004241 · rdgdoc.xml · nonDerivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,000

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-004239 · rdgdoc.xml · nonDerivative · entry 1

Kumar Hermant · CIK 0001884546 · Chief Mfgr & Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value, on a one-to-one basis.

SEC source: 0001437749-23-004235 · rdgdoc.xml · nonDerivative · entry 1

Varner John Rodney · CIK 0001735543 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,159,735

F1 · shares: This award of Restricted Stock Units ("RSUs") is granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan and vests in installments of 50% on the first anniversary of the date of grant and the remaining 50% on the second anniversary of the date of grant. Vested RSUs will be paid in shares of the Company's common stock, $0.001 par value ("Common Stock") on a one-to-one basis.

F2 · balance_after: This total now excludes 10,000 shares of Common Stock that were previously reported as being purchased on March 29, 2018 and directly held by Reporting Person. The prior inclusion of these shares was inadvertent and due to an administrative error.

SEC source: 0001437749-22-018277 · rdgdoc.xml · derivative · entry 2

Confer Ryan M. · CIK 0001735541 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 116,973 shares

Expires 2022-07-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-22-018277 · rdgdoc.xml · nonDerivative · entry 1

Confer Ryan M. · CIK 0001735541 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,499

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-22-016004 · rdgdoc.xml · derivative · entry 1

Wilson William R Jr. · CIK 0001807385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,368

Underlying: Common Stock · 83,368 shares

Expires 2032-06-23

F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 23, 2022, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy.

F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 23, 2022 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-22-016010 · rdgdoc.xml · derivative · entry 1

Moreno Toscano Jose Antonio · CIK 0001807313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,368

Underlying: Common Stock · 83,368 shares

Expires 2032-06-23

F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 23, 2022, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy.

F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 23, 2022 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-22-016005 · rdgdoc.xml · derivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,368

Underlying: Common Stock · 83,368 shares

Expires 2032-06-23

F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 23, 2022, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy.

F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 23, 2022 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-22-016003 · rdgdoc.xml · derivative · entry 1

Kumar Hermant · CIK 0001884546 · Chief Mfgr & Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2032-06-23

F1 · derivative.exercise_date: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of June 23, 2022 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of June 23, 2022 provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-22-002752 · rdgdoc.xml · derivative · entry 1

VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2032-02-04

F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date.

SEC source: 0001437749-22-002748 · rdgdoc.xml · derivative · entry 1

Confer Ryan M. · CIK 0001735541 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,750

Underlying: Common Stock · 341,750 shares

Expires 2032-02-04

F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date.

SEC source: 0001437749-22-002746 · rdgdoc.xml · derivative · entry 1

Varner John Rodney · CIK 0001735543 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,062,250

Underlying: Common Stock · 1,062,250 shares

Expires 2032-02-04

F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date.

SEC source: 0001437749-22-002744 · rdgdoc.xml · derivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,750

Underlying: Common Stock · 98,750 shares

Expires 2032-02-04

F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date.

SEC source: 0001437749-22-002742 · rdgdoc.xml · derivative · entry 1

Kumar Hermant · CIK 0001884546 · Chief Mfgr & Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,312

Underlying: Common Stock · 54,312 shares

Expires 2032-02-04

F1 · derivative.exercise_date: The option (the "Option") was granted under the Genprex, Inc. (the "Company") 2018 Equity Incentive Plan (the "Plan"). The Option shall vest and become exercisable as to one third (1/3) of the total number of shares (the "Shares") of the Company's common stock, $.001 par value subject to the Option on February 4, 2023 (the "Vesting Commencement Date") and thereafter shall vest and become exercisable as to an additional 1/24 of the remaining Shares subject to the Option on each monthly anniversary of the Vesting Commencement Date until fully vested and exercisable, in each case provided that the Optionee continues to serve as a Service Provider (as defined in the Plan) through the applicable vesting date.

SEC source: 0001437749-21-022778 · rdgdoc.xml · derivative · entry 1

Kumar Hermant · CIK 0001884546 · Chief Mfgr & Tech Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2031-09-27

F1 · security: The options were granted outside of the Registrant's incentive award plans as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: One-third of the options will vest on each of the first, second and third anniversaries of the date on which the Reporting Person commences employment with the Registrant.

SEC source: 0001437749-21-022776 · rdgdoc.xml · derivative · entry 1

Berger Mark Stanley · CIK 0001700283 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,000

Underlying: Common Stock · 550,000 shares

Expires 2031-09-27

F1 · security: The options were granted outside of the Registrant's incentive award plans as an inducement grant pursuant to Nasdaq Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: One-third of the options will vest on each of the first, second and third anniversaries of the date on which the Reporting Person commences employment with the Registrant.

SEC source: 0001437749-21-015723 · rdgdoc.xml · derivative · entry 1

Moreno Toscano Jose Antonio · CIK 0001807313 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,376

Underlying: Common Stock · 32,376 shares

Expires 2031-06-24

F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 24, 2021, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy.

F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 24, 2021 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-21-015726 · rdgdoc.xml · derivative · entry 1

Wilson William R Jr. · CIK 0001807385 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,376

Underlying: Common Stock · 32,376 shares

Expires 2031-06-24

F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 24, 2021, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy.

F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 24, 2021 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-21-015721 · rdgdoc.xml · derivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,376

Underlying: Common Stock · 32,376 shares

Expires 2031-06-24

F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 24, 2021, the date on which the option grant was made under the Genprex, Inc. Outside Director Compensation Policy.

F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 24, 2021 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.

SEC source: 0001437749-22-003281 · rdgdoc.xml · nonDerivative · entry 1

Varner John Rodney · CIK 0001735543 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Laura Lane Biosciences, LLC

Disclosed balance after: 0

F1 · acquired: On June 14, 2021, Mr. Varner resigned as the manager of Laura Lane Biosciences, LLC, and Mr. Varner and his spouse resigned as trustees of the trusts that comprise all of the members of Laura Lane Biosciences, LLC.

SEC source: 0001437749-21-008469 · rdgdoc.xml · nonDerivative · entry 1

LONGNECKER BRENT M · CIK 0001218777 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · price: The price reported is a weighted average price. A total of 15,000 shares were purchased in multiple transactions at prices ranging from $4.1375 per share to $4.16 per share.

SEC source: 0001437749-21-006914 · rdgdoc.xml · derivative · entry 1

VACZY CATHERINE M · CIK 0001177176 · EVP GC Chief Strategy Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2031-03-19

F1 · derivative.exercise_date: One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.